Autres langues Purple Biotech Ltd

Actions

PPBT

IL0007650166

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 16:24:55 30/04/2024			Varia. 5j.	Varia. 1 janv.
21 ^ILa	-1,41 %		+4,48 %	-34,17 %

25/04	L'étude randomisée de phase 2 CM24 sur le cancer du pancréas de Purple Biotech Ltd. a été sélectionnée pour la présentation d'un poster de résumé de dernière minute lors de la réunion annuelle de l'ASCO 2024.	CI
14/03	Purple Biotech rapporte une preuve de concept préclinique pour sa plateforme technologique Tribody	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25/04
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	28/03
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14/03
Purple Biotech : Immediate Report	06/03
6K:Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27/02
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	27/02
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	13/02
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	01/02
Purple Biotech Ltd. Announces Executive Changes	20/12
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	30/11
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11
Purple Biotech Reports Third Quarter 2023 Financial Results	21/11
Purple Biotech Fortifies NT219 Patent Protection	02/11
Purple Biotech : Other Report or Announcement	31/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Purple Biotech Ltd

Actions

PPBT

IL0007650166

Autres langues

Filtres